市場調査レポート

バイオテクノロジー関連支援取引およびパートナーシップ:最近のベンチャー資本、企業投資資金およびその他取引の分析

Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions

発行 Kalorama Information 商品コード 304898
出版日 ページ情報 英文 156 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.16円で換算しております。
Back to Top
バイオテクノロジー関連支援取引およびパートナーシップ:最近のベンチャー資本、企業投資資金およびその他取引の分析 Biotech Funding Deals and Partnerships: Analysis of Recent Venture Capital and Corporate Capital Funding and Other Transactions
出版日: 2014年05月20日 ページ情報: 英文 156 Pages
概要

企業の投資額の8分の1近くはバイオテクノロジーに対する投資になっています。過去数年間においてバイオテクノロジーに対する投資は大幅に増えており、この結果として、完全な買収からライセンス契約や、多様な提携取引など、一連の複雑な取引や商談が行われてきました。これらの企業資本の流入に加え、バイオテクノロジー企業は大幅なベンチャー資本の流入も目の当たりにしてきています。

当レポートでは、バイオテクノロジー部門における投資事情を取り上げ、最近・現在・将来の投資状況を調査分析する中で56の主要なバイオテクノロジー取引の財務的な詳細および治療薬の可能性を概括し、ベンチャー資本の投資動向をまとめています。

第1章 エグゼクティブサマリー

  • 主な調査結果
  • 調査手法

第2章 イントロダクション

  • 調査の趣旨
    • 投資が重要である理由
    • 種まき段階以降
    • 価値促進要因の特定

第3章 動向と見通し

  • 企業ベンチャー資本がM&A活動に拍車をかける
  • 成長が見込まれるライセンス供与取引
  • 堅調なベンチャー資本の展望
  • 注目される治療分野
  • 新たな戦略の必要性
    • 成功可能性のモデル化
    • クラウドファンディング
      • 生命線

第4章 洗練された協調体制による成長

  • 製品価値の決定
    • 定量化可能な問題
    • 革命的な価値
    • 国際的な価値
  • 変化する役割と市場情勢

第5章 ベンチャー資本 VS 企業資本

  • 新たな資金調達の展望
  • 戦略で武装化されたベンチャー
  • 企業資本の基本

第6章 投資資金の動向

  • 年別指標
  • オーダーメイド医療

第7章 主な取引(56社:取引概要、規模、契約形態、詳細、治療薬紹介と潜在力)

  • Ablynx NV
  • Acetylon Pharmaceuticals Inc.
  • AC Immune SA
  • Adimab
  • Aileron Therapeutics Inc.
  • Algeta ASA
  • Alios BioPharma Inc.
  • Alkermes
  • Alnylam Pharmaceuticals
  • Amylin Pharmaceuticals
  • Ardea Biosciences
  • Atara Biotherapeutics
  • Avila Therapeutics
  • Boston Biomedical
  • Cellectis
  • Clarus Ventures
  • CoStim Pharmaceuticals
  • Covagen AG
  • Dicerna Pharmaceuticals Inc.
  • Editas Medicine
  • Enanta Pharmaceuticals Inc.
  • Endocyte Inc.
  • Evotec AG
  • Forma Therapeutics
  • Galapagos NV
  • Gemin X Pharmaceuticals
  • Genmab
  • GlaxoSmithKline
  • Human Genome Sciences
  • immatics Biotechnologies GmbH
  • Inhibitex
  • Inhibrx
  • Isis Pharmaceuticals Inc.
  • Juno Therapeutics
  • Macrogenics Inc.
  • Mannkind Corp.
  • Medigene AG
  • Melinta Therapeutics
  • Merck
  • Mesoblast Ltd.
  • Micromet AG
  • Moderna Therapeutics Inc.
  • OncoMed Pharmaceuticals Inc.
  • Onyx Pharmaceuticals Inc.
  • Otonomy Inc.
  • Pharmasset
  • Plexxikon Inc.
  • Reata Pharmaceuticals
  • Royalty Pharma
  • Seattle Genetics Inc.
  • Sutro Biopharma Inc.
  • Thesan Pharmaceuticals Inc.
  • UCB Inc.
  • Voyager Therapeutics
  • Xenon Pharmaceuticals Inc.
  • Xoma Corp.
目次
Product Code: KLI5248409

Recent Biotech Funding, Deals and Partnerships

Nearly one out of every 8 dollars invested in companies are invested in biotech. Biotech investment has increased significantly in the past few years, and 2013 saw a notable spike. In the last few years, this has resulted in a complex series of deals and transactions, ranging from complete buyouts, to licensing transactions, to a variety of collaborative arrangements. In addition to this influx of corporate capital, biotechnology companies have seen a significant influx of venture capital, as investors invest in new science and technology that they believe have potential in the clinic.

This Kalorama Information report, Recent Biotech Funding Deals and Partnerships, attempts to provide clarity on the phenomenon. The report analyzes the recent, current and potential landscape for investing in the biotechnology sector.

Included in the report's coverage are the following data points

  • 56 Key Biotech Deals Analyzed: Financial Details and Therapeutic Potential
  • Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013 (in US billions)
  • Health Care as a Percentage of Total Venture Investment, 2009-2012 (in US billions)
  • Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million
  • Number of Biotech Series A Companies by Indication Oncology,
  • Platform Discovery, Diagnostics, CNS, Autoimmune)
  • Biotech Total Deal Value, 2005-2012
  • IPO Statistics
  • Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013

Analyzed are both venture and corporate capital funding efforts. In addition, the report looks at other collaborative approaches, including licensing, joint ventures and partnerships aimed at moving product candidates into the market place as approved therapies, especially if they address unmet medical needs.

This report also reviews the nature and direction of funding trends, and reviews the important role that investments play in moving technology into the market place. The report profiles several biotechnology sector companies and the deals that they were involved in from 2011 to 2014. Some of the companies and transactions profiled in the report include: Alkermes, Boston Biomedical, Dicerna Pharmaceuticals, immatics biotechnologies, Micromet, Reata Pharmaceuticals, UCB and Xoma.

The information presented in this report is the result of data gathered from company product literature and other corporate brochures and documents, as well as information found in the scientific and trade press. In addition, interviews were conducted with executives and analysts.

The following are among the companies covered in this report:

  • Abbott
  • AC Immune SA
  • Adimab
  • Aileron Therapeutics Inc.
  • Atara Biotherapeutics
  • Boston Biomedical
  • Cellectis
  • Clarus Ventures
  • CoStim Pharmaceuticals
  • Covagen AG
  • Dicerna Pharmaceuticals Inc.
  • Editas Medicine
  • Enanta Pharmaceuticals Inc.
  • Endocyte Inc.
  • Evotec
  • Forma Therapeutics
  • Galapagos NV
  • Mannkind Corp.
  • Melinta Therapeutics
  • Micromet
  • Novartis
  • OncoMed
  • Onyx Pharmaceuticals Inc.
  • Otonomy Inc.
  • Pharmasset
  • Seattle Genetics Inc.
  • Royalty Pharma
  • Roche
  • Sutro Biopharma Inc.
  • Thesan Pharmaceuticals Inc.
  • UCB Inc.
  • Voyager Therapeutics
  • Xenon Pharmaceuticals Inc.
  • Xoma Corp.

Table of Contents

1.0. EXECUTIVE SUMMARY

  • 1.1. Key Findings
  • 1.2. Methodology

2.0. INTRODUCTION

  • 2.1. Reason for the Report
    • 2.1.1. Why Investing Is Important
    • 2.1.2. Beyond the Seed Stage
    • 2.1.3. Identify Value Drivers

3.0. TRENDS AND EXPECTATIONS

  • 3.1. Corporate Venture Capital Spurs M&A Activity
  • 3.2. Licensing Deals to Grow
  • 3.3. Venture Capital's Strong Outlook
  • 3.4. Therapeutic Areas of Focus
    • 3.4.1. The Outcomes Push
  • 3.5. In Need of New Strategies
    • 3.5.1. Modeling Potential Success
    • 3.5.2. Crowdfunding
      • 3.5.2.1. A Lifeline

4.0. GROWTH THROUGH SOPHISTICATED COLLABORATIONS

  • 4.1. Determining Product Value
    • 4.1.1. Quantifiable Issues
    • 4.1.2. Revolutionary Value
    • 4.1.3. Global Value
  • 4.2. Changing Roles and Market Landscapes

5.0. VENTURE CAPITAL VS. CORPORATE CAPITAL

  • 5.1. New Fundraising Vistas
  • 5.2. Venture Arms with a Strategy
  • 5.3. Corporate Capital Fundamentals

6.0. INVESTMENT DOLLAR TRENDS

  • 6.1. Annual Numbers
    • 6.1.1. Trends in 2013
    • 6.1.2. Trends in 2012
    • 6.1.3. Trends in 2011
    • 6.1.4. Trends in 2010
    • 6.1.5. Trends in 2009
  • 6.2. Personalized Medicine

7.0. KEY DEALS

  • 7.1. Ablynx NV
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.2. Acetylon Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.3. AC Immune SA
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.4. Adimab
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.5. Aileron Therapeutics Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.6. Algeta ASA
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.7. Alios BioPharma Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.8. Alkermes
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.9. Alnylam Pharmaceuticals
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.10. Amylin Pharmaceuticals
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.11. Ardea Biosciences
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.12. Atara Biotherapeutics
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.13. Avila Therapeutics
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.14. Boston Biomedical
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.15. Cellectis
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.16. Clarus Ventures
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.17. CoStim Pharmaceuticals
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.18. Covagen AG
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.19. Dicerna Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.20. Editas Medicine
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.21. Enanta Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.22. Endocyte Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.23. Evotec AG
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.24. Forma Therapeutics
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.25. Galapagos NV
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.26. Gemin X Pharmaceuticals
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.27. Genmab
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.28. GlaxoSmithKline
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.29. Human Genome Sciences
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.30. immatics Biotechnologies GmbH
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.31. Inhibitex
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.32. Inhibrx
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.33. Isis Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.34. Juno Therapeutics
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.35. Macrogenics Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.36. Mannkind Corp.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.37. Medigene AG
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.38. Melinta Therapeutics
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.39. Merck
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.40. Mesoblast Ltd.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.41. Micromet AG
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.42. Moderna Therapeutics Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.43. OncoMed Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.44. Onyx Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.45. Otonomy Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.46. Pharmasset
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.47. Plexxikon Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.48. Reata Pharmaceuticals
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.49. Royalty Pharma
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.50. Seattle Genetics Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.51. Sutro Biopharma Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.52. Thesan Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.53. UCB Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.54. Voyager Therapeutics
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.55. Xenon Pharmaceuticals Inc.
    • Description of Deal
    • Size
    • Agreement Type
    • Details
    • Therapeutic Background and Potential
  • 7.56. Xoma Corp.
    • Description of Deal
    • Size
    • Agreement Type
    • Details

LIST OF EXHIBITS

1.0 EXECUTIVE SUMMARY

  • Summary Exhibit: Biotechnology Investment Dollars, 2012 and 2013 ($ millions)

6.0 INVESTMENT DOLLAR TRENDS

  • Exhibit 1: Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013
  • Exhibit 2: Venture Capital Dollar Trends, Overall Dollars Invested 2009-2013
  • Exhibit 3: Venture Capital Dollar Trends, Biotechnology Dollars Invested 2009-2013
  • Exhibit 4: Venture Capital Dollar Trends, Biotechnology Dollars Invested 2009-2013
  • Exhibit 5: Breakdown of Overall and Biotech Venture Capital Dollars, Billions of Dollars US Invested in 2013
  • Exhibit 6: Venture Capital Dollar Trends, Biotechnology Dollars Invested by Quarter, 2009-2013
  • Exhibit 7: Health Care as a Percentage of Total Venture Investment, 2009-2012
  • Exhibit 8: Biotech Companies Raising Series A Dollars, 2009-2012, Greater than $2 Million
  • Exhibit 9: Number of Biotech Series A Companies by Indication, 2009, Raising More than $2 Million
  • Exhibit 10: Number of Biotech Series A Companies by Indication, 2010, Raising More Than $2 Million
  • Exhibit 11: Number of Biotech Series A Companies by Indication, 2011, Raising More Than $2 Million
  • Exhibit 12: Number of Biotech Series A Companies by Indication, 2012, Raising More Than $2 Million
  • Exhibit 13: Biotech Total Deal Value, 2005-2012, Minimum Two Big Exits
  • Exhibit 14: Personalized Medicine M&A with Disclosed Values, 2010-2013
  • Exhibit 15: Personalized Medicine Disclosed M&A Number of Deals by Focus, 2010-2013
  • Exhibit 16: Personalized Medicine Disclosed M&A Deal Value by Focus, 2010-2013
  • Exhibit 17: Personalized Medicine Financings, 2010-2013
  • Exhibit 18: Personalized Medicine Financings by Type, Number of Deals, 2010-2013
  • Exhibit 19: Personalized Medicine Financings by Category, Number of Deals, 2010-2013
Back to Top